Exothera is a viral vector CDMO (contract development and manufacturing organization) leveraging standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies. Pall Corporation recently partnered with Exothera and supported them in the expansion of their manufacturing capabilities by adding a large-scale suspension-based manufacturing platform, from upstream through downstream processing of viral vectors of up to 2000 L.
Join this webinar and hear from Exothera as they explain their journey towards scale-up.
Global Product Manager, Integrated Solutions, Pall Corporation
Dave is a Global Product Manager covering the Integrated Solutions program, responsible for marketing operations, outbound marketing and customer research. He joined us in 2016, bringing 11 years of both scientific and engineering experience in the areas of product development, project management, R&D and marketing. He holds degrees in both Microbiology and Mechanical Engineering from the University of Massachusetts, Amherst. In his spare time, Dave enjoys hiking, brewing beer and cider, and cooking various international cuisines using freshly grown ingredients from his garden.
Hanna P. Lesch Ph.D.
Chief Technology Officer, Exothera
Hanna has made her whole career in the gene therapy field. Over the years she has been in several directors’ positions leading research and development at FKD Therapies, Finvector and Kuopio Center for Gene and Cell Therapy. Her research interest has focused on gene therapy and translational development, including early stage analyticals and the development of scalable, robust manufacturing processes operating under current regulatory guidelines. Her PhD was in Molecular Medicine, obtained from the University of Kuopio. She followed up her PhD with post doc work at the University of California San Diego UCSD, CA, USA, and the University of Eastern Finland, Kuopio, Finland. She has several patents related to vector manufacturing.
Chief Operating Officer, Exothera
As COO, Christian leads the R&D operations in our Gosselies and Nivelles facilities. He conducts his teams to implement organizational strategy at all levels while assuring the proper management and incorporation of our development projects with our ongoing incorporation of new technologies into our platform.
Christian brings over twenty-five years of expertise in biopharmaceutical manufacturing and supply chain management to support Univercells’ next steps. In addition to his most recent work in leading roles as QA SME & Compliance Remediation Project Leader (Lonza) and Site Leader (Pfizer/Zoetis), he benefits from his strong experience gained while at Pfizer and SmithKline Beecham in lead QA and manufacturing positions. His extensive background in these fields enables our team to build upon his experience to build productive collaborations and effective project delivery.
Mr. Borgniet holds master’s degrees from the Université Catholique de Louvain in Pharmacy and Pharmaceutical Engineering and from the Université Saint-Louis Brussels in Business Administration and Management. Additionally, he has completed the rigorous Executive Leadership Program at INSEAD.